Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available. Lansoprazole is a racemate 1:1-mixture of the enantiomersdexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.
Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours, and the effects of the drug last for over 24 hours after it has been used for 1 day or more. Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.
Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics. Treatment to kill Helicobacter pylori (H. pylori) causing ulcers or other problems involves using two other drugs besides lansoprazole. This treatment is known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg.
Proton-pump inhibitors may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea. Antacid preparations such as lansoprazole suppress acid-mediated breakdown of proteins, leading to an elevated risk of developing food and drug allergies. This happens due to undigested proteins passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well. Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.
Prevacid 30 mg
Lansoprazole is available as a generic drug in the US, Russian Federation, UK, Canada, Belgium,Brazil, Finland, France, Colombia, Italy, Sweden, and Mexico.
The drug is also sold under several brand names, including:
^Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag